Published in Int J Radiat Oncol Biol Phys on December 16, 2010
Urethroplasty after radiation therapy for prostate cancer. Urology (2012) 2.11
Systematic review: anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis (2013) 1.00
Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. Radiat Oncol (2013) 0.84
Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy. Br J Cancer (2013) 0.82
Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last? J Urol (2012) 0.81
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil. Radiat Oncol (2014) 0.80
Urethral strictures after radiation therapy for prostate cancer. Investig Clin Urol (2016) 0.78
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol (2015) 0.77
Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer. Front Oncol (2015) 0.77
Management of radiation-induced urethral strictures. Transl Androl Urol (2015) 0.76
Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer. Res Rep Urol (2013) 0.75
Presentation, management, and outcomes of complications following prostate cancer therapy. Transl Androl Urol (2014) 0.75
Feasibility of normal tissue dose reduction in radiotherapy using low strength magnetic field. Radiat Oncol J (2015) 0.75
A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin. Am J Clin Oncol (2016) 0.75
Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial. JMIR Res Protoc (2015) 0.75
Management of bladder neck stenosis and urethral stricture and stenosis following treatment for prostate cancer. Transl Androl Urol (2017) 0.75
Effect of modern, high-quality prostate intensity-modulated radiation therapy on outcome: Evidence from a community radiation oncology program. Mol Clin Oncol (2017) 0.75
Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2002) 3.93
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol (2010) 3.59
All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci (2002) 3.31
IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest (2009) 3.30
Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2003) 2.56
Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol (2006) 2.39
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol (2004) 2.27
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol (2006) 2.22
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest (2003) 2.22
Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol (2009) 2.18
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest (2012) 2.00
What do recent studies on lumpectomy cavity volume change imply for breast clinical target volumes? Int J Radiat Oncol Biol Phys (2008) 1.94
Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst (2003) 1.89
Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2003) 1.89
Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol (2013) 1.76
Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation. Int J Radiat Oncol Biol Phys (2007) 1.75
Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg (2007) 1.61
Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.61
Vagus nerve stimulation mediates protection from kidney ischemia-reperfusion injury through α7nAChR+ splenocytes. J Clin Invest (2016) 1.56
Subclinical hypertensive heart disease in black patients with elevated blood pressure in an inner-city emergency department. Ann Emerg Med (2012) 1.54
Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. Biochemistry (2007) 1.53
Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol (2005) 1.52
Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause (2003) 1.50
Predicting comatose patients with acute stroke outcome using middle-latency somatosensory evoked potentials. Clin Neurophysiol (2011) 1.49
American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy (2012) 1.45
Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys (2010) 1.42
Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol (2013) 1.42
Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol (2010) 1.41
Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics (2013) 1.38
Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.33
High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.33
Interplay between the Smc5/6 complex and the Mph1 helicase in recombinational repair. Proc Natl Acad Sci U S A (2009) 1.31
Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol (2010) 1.31
Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys (2002) 1.30
Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.27
Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.27
Architecture of the Smc5/6 Complex of Saccharomyces cerevisiae Reveals a Unique Interaction between the Nse5-6 Subcomplex and the Hinge Regions of Smc5 and Smc6. J Biol Chem (2009) 1.23
The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy (2013) 1.23
Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys (2008) 1.23
Copper cofactor delivery in plant cells. Curr Opin Plant Biol (2006) 1.22
Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy. Int J Radiat Oncol Biol Phys (2005) 1.21
Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg (2005) 1.20
Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol (2011) 1.19
Changes in the respiratory pattern during radiotherapy for cancer in the lung. Radiother Oncol (2006) 1.19
Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys (2007) 1.17
Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys (2010) 1.15
Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys (2009) 1.14
Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol (2008) 1.14
Computed tomography guided management of interfractional patient variation. Semin Radiat Oncol (2005) 1.12
Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol (2003) 1.08
Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol (2012) 1.07
Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int (2008) 1.07
Gli1 induces G2/M arrest and apoptosis in hippocampal but not tumor-derived neural stem cells. Stem Cells (2008) 1.06
Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer (2003) 1.06
Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol (2005) 1.06
Impaired adult neurogenesis in mice lacking the transcription factor E2F1. Mol Cell Neurosci (2002) 1.04
Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial. Ann Surg Oncol (2013) 1.03
Iron-sulfur cluster biogenesis in chloroplasts. Involvement of the scaffold protein CpIscA. Plant Physiol (2005) 1.03
Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int J Radiat Oncol Biol Phys (2011) 1.03
Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol (2005) 1.03
Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol (2002) 1.02
Partial breast irradiation in breast conserving therapy by way of intersitial brachytherapy. Am J Surg (2004) 1.02
Synthesis of macrocycles via cobalt-mediated [2 + 2 + 2] cycloadditions. J Am Chem Soc (2005) 1.02
Structural and functional insights into the roles of the Mms21 subunit of the Smc5/6 complex. Mol Cell (2009) 1.01
Characterization of Arabidopsis thaliana SufE2 and SufE3: functions in chloroplast iron-sulfur cluster assembly and Nad synthesis. J Biol Chem (2007) 1.00
Butenyl-spinosyns, a natural example of genetic engineering of antibiotic biosynthetic genes. J Ind Microbiol Biotechnol (2005) 1.00
High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys (2011) 1.00
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg (2006) 0.99
Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys (2007) 0.98
Wedge resection margin distances and residual adenocarcinoma in lobectomy specimens. Am J Clin Pathol (2003) 0.98
Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys (2005) 0.97
Differential gene induction by genetic and ligand-mediated activation of the Sonic hedgehog pathway in neural stem cells. Dev Biol (2007) 0.97
Limitations of the American Society of Therapeutic Radiology and Oncology Consensus Panel guidelines on the use of accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys (2010) 0.97
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys (2011) 0.97
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2012) 0.97